EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

State of Precision Oncology: An Australian Perspective

Samrin Liaqat iD, Muhammad Adnan Khattak iD

Journal of Immunotherapy and Precision Oncology · 05.11.2026 · 9 (4) · 260-267

DOI: 10.36401/jipo-25-29 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Immunotherapy and Precision Oncology, erschienen am 05.11.2026. Verfasst von Samrin Liaqat und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Alan Walker Cancer Care Centre, Royal Darwin Hospital, Northern Territory, Australia. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Precision oncology is redefining cancer therapeutics worldwide. In Australia, the integration of genomic medicine into routine clinical oncology remains inconsistently constrained by fragmented funding mechanisms, regional disparities, and a limited workforce. Understanding these structural and policy challenges is crucial for transitioning toward a sustainable, equitable genomic health ecosystem. This narrative review synthesizes evidence from national policy frameworks, peer-reviewed literature, and translational oncology initiatives to examine the current state of precision oncology in Australia. Key domains of analysis include clinical practice patterns, access and equity, infrastructure, data governance, regulatory oversight, and health-policy reform. Although major initiatives, such as Omico’s Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) platform, the ZERO Childhood Cancer Program, and the forthcoming national coordination body Genomics Australia, demonstrate substantial progress, significant implementation barriers persist. Australia stands on the cusp of realizing a genomics-enabled model of cancer care. Consolidation of national governance under Genomics Australia, expansion of Medicare Benefits Schedule reimbursement for comprehensive genomic profiling, and integration of digital-innovation platforms will be pivotal to achieving an internationally replicable model for responsible, population-wide precision oncology.

Schlagwörter

Stichwörter der Autor:innen

Australiacomprehensive genomic profilingfuturegenomicsprecision medicine

Autor:innen und Institutionen

  • Department of Medical Oncology, Alan Walker Cancer Care Centre, Royal Darwin Hospital, Northern Territory, Australia.
  • Department of Medical Oncology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
  • Edith Cowin University, Western Australia, Australia.

ORCID-Profile: Samrin Liaqat, Muhammad Adnan Khattak

Zitieren

APA

Liaqat, S., & Khattak, M. A. (2026). State of Precision Oncology: An Australian Perspective. Journal of Immunotherapy and Precision Oncology, 9(4), 260-267. https://doi.org/10.36401/jipo-25-29

Vancouver

Liaqat S, Khattak MA. State of Precision Oncology: An Australian Perspective. Journal of Immunotherapy and Precision Oncology. 2026;9(4):260-267. doi:10.36401/jipo-25-29

BibTeX
@article{Liaqat2026,
  author = {Liaqat, Samrin and Khattak, Muhammad Adnan},
  title = {State of Precision Oncology: An Australian Perspective},
  journal = {Journal of Immunotherapy and Precision Oncology},
  year = {2026},
  volume = {9},
  number = {4},
  pages = {260--267},
  doi = {10.36401/jipo-25-29}
}
Kostenlos starten →